Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kamada Ltd (KMDA)

Kamada Ltd (KMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Pharmaceutical Stocks Under $10 to Buy in September

The pharmaceutical industry’s increased focus on developing better treatments for many of today's most complex diseases should help it to grow for the foreseeable future. However, because highly priced...

AMRX : 5.21 (+3.37%)
CPRX : 5.05 (+3.06%)
KMDA : 5.37 (+1.13%)
3 Under the Radar Pharmaceutical Stocks to Add to Your Watchlist

The pharmaceutical industry is expected to attract significant investor attention in the coming months as the demand for vaccines and therapies continues to soar with the resurgence of COVID-19 cases globally....

CPRX : 5.05 (+3.06%)
KMDA : 5.37 (+1.13%)
OPNT : 25.40 (+5.83%)
New Strong Sell Stocks for August 25th

BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021

CHRS : 17.52 (+2.70%)
KMDA : 5.37 (+1.13%)
STIM : 6.73 (+5.82%)
PHUN : 0.9979 (+1.31%)
BEEM : 30.44 (+3.68%)
Kamada (KMDA) Q2 Earnings and Revenues Miss Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

KMDA : 5.37 (+1.13%)
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2021.

KMDA : 5.37 (+1.13%)
Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and six months ended June 30, 2021, prior to the open...

KMDA : 5.37 (+1.13%)
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KMDA : 5.37 (+1.13%)
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

GILD : 71.69 (+0.43%)
RGEN : 324.21 (+3.55%)
TECH : 536.90 (+0.73%)
KMDA : 5.37 (+1.13%)
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

RGEN : 324.21 (+3.55%)
TECH : 536.90 (+0.73%)
KMDA : 5.37 (+1.13%)
BPMC : 109.47 (+0.26%)
CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases

CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.

VRTX : 185.09 (+0.44%)
BAYRY : 13.7400 (+0.81%)
KMDA : 5.37 (+1.13%)
CRSP : 121.25 (+2.92%)

Barchart Exclusives

Platinum- The Not So Precious Metal That Loves To Disappoint
This week, platinum probed below the $900 per ounce level for the first time in 2021. While platinum is the precious metal that offers the most compelling value proposition, the price action remains bearish in late September. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar